Sleep disturbance in schizophrenia. A revisit.
Rapid eye movement (REM) sleep mechanisms may play a role in the pathophysiology of schizophrenia, but results have been inconclusive and studies of sleep in schizophrena have been deficient in identifying, comparing, and differentiating between subcategories of schizophrenia. Twenty-nine hospitalized, drug-free schizophrenics were divided into three subgroupsācute, latent, and schizoaffective. The REM intensity measures and REM latency were found to differentiate significantly the schizoaffective group. Sleep-continuity indexes separated the latent and acute groups. Seven patients who later required treatment with tricyclic an tidepressants had base line REM latencies significantly lower and hospitalizations significantly more prolonged than the patients who did not require antidepressants. Sleep measurements may thus identify diagnostic subgroups of schizophrenia as well as predict which schizophrenic depressive syndrome or a concurrent affective syndrome.
D000208:Acute Disease; D000328:Adult; D000342:Affective Symptoms / Q000150:complications / Q000188:drug therapy; D000367:Age Factors; D000928:Antidepressive Agents / Q000627:therapeutic use; D004569:Electroencephalography; D004576:Electromyography; D004585:Electrooculography; D005260:Female; D006212:Hallucinations; D006801:Humans; D008297:Male; D010640:Phenothiazines / Q000627:therapeutic use; D011619:Psychotropic Drugs / Q000627:therapeutic use; D012559:Schizophrenia / Q000145:classification / Q000188:drug therapy; D012569:Schizotypal Personality Disorder / Q000145:classification / Q000188:drug therapy; D012890:Sleep; D012895:Sleep, REM
D000928:Antidepressive Agents; D010640:Phenothiazines; D011619:Psychotropic Drugs